Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Blonde

Showing results (31-40 of 144) with videos related to

Pageof 15
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 6, 2014
Fixed-dose combination therapy in type 2 diabetes mellitusLawrence Blonde, Zinnia T San Juan, Peggy Bolton
Diabetes, Obesity & Metabolism|April 21, 2021
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programmeLawrence Blonde, Timothy Bailey, Sean D Sullivan, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|March 3, 2020
Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and ConsequencesSusan L Karam, Jared Dendy, Shruti Polu, et al.
Postgraduate Medicine|June 12, 2014
Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agentsMary Ann Banerji, Michelle A Baron, Ling Gao, et al.
Clinical Drug Investigation|February 20, 2016
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given AloneTina Vilsbøll, Jiten Vora, Henrik Jarlov, et al.
Diabetes, Obesity & Metabolism|March 15, 2018
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world studyOlga Montvida, Jonathan E Shaw, Lawrence Blonde, et al.
Current Medical Research and Opinion|October 30, 2018
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetesLawrence Blonde, John E Anderson, Pavan Chava, et al.
JAMA|June 2, 2005
Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trialJayant Dey, Lawrence Blonde, Alan Burshell, et al.
Journal of the American Academy of Nurse Practitioners|October 27, 2006
Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education ProgramLawrence Blonde, Judith Dempster, Joanne M Gallivan, et al.
Diabetes Care|December 24, 2005
The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetesWilliam T Cefalu, Steven R Smith, Lawrence Blonde, et al.
Pageof 15

Showing results (31-40 of 144) with videos related to

Sort By:
Pageof 15
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 6, 2014
Fixed-dose combination therapy in type 2 diabetes mellitusLawrence Blonde, Zinnia T San Juan, Peggy Bolton
Diabetes, Obesity & Metabolism|April 21, 2021
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programmeLawrence Blonde, Timothy Bailey, Sean D Sullivan, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|March 3, 2020
Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and ConsequencesSusan L Karam, Jared Dendy, Shruti Polu, et al.
Postgraduate Medicine|June 12, 2014
Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agentsMary Ann Banerji, Michelle A Baron, Ling Gao, et al.
Clinical Drug Investigation|February 20, 2016
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given AloneTina Vilsbøll, Jiten Vora, Henrik Jarlov, et al.
Diabetes, Obesity & Metabolism|March 15, 2018
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world studyOlga Montvida, Jonathan E Shaw, Lawrence Blonde, et al.
Current Medical Research and Opinion|October 30, 2018
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetesLawrence Blonde, John E Anderson, Pavan Chava, et al.
JAMA|June 2, 2005
Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trialJayant Dey, Lawrence Blonde, Alan Burshell, et al.
Journal of the American Academy of Nurse Practitioners|October 27, 2006
Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education ProgramLawrence Blonde, Judith Dempster, Joanne M Gallivan, et al.
Diabetes Care|December 24, 2005
The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetesWilliam T Cefalu, Steven R Smith, Lawrence Blonde, et al.
Pageof 15